Extracts of Bacopa monnieri (L) Pennell Down-Regulate the Expression of Leukotriene C4 Synthase mRNA in HL-60 Cells and Suppress OVAInduced Inflammation in BALB/c Mice
Aims: To investigate the in vitro and in vivo anti-inflammatory effects of Bacopa monnieri extracts in HL-60 cells and in OVA-induced airway inflammation in BALB/C mice.
Materials and Methods: Bacopa monnieri (Brahmi) leaves and stems were collected in Vidisha (M.P.), India, identified and air-dried. The dried plant materials were pulverized to a powder, extracted in methanol to exhaustion, dried and fractionated. The extracts and fractions were tested for their effects on leukotriene C4 synthase, leukotriene A4hydrolase and cyclooxygenase-2 in HL-60 cells. The active dried methanol extract of B. monnieri was then tested in vivo in an OVAinduced asthma mouse model and inflammation was assessed using 2-D imaging.
Results: Bacopa monnieri extracts and partitions inhibited leukotriene-C4-synthase, leukotriene-A4-hydrolase and/or cyclooxygenase- 2 (COX-2) activities in cultured HL-60 cells. The EtOAc partition of the extracts inhibited the activity of leukotriene-C4-synthase by 69%, and down-regulated the expression of the mRNA of this enzyme in HL-60 cells. The results demonstrated significant inhibition of leukotriene-C4-synthase, leukotriene-A4-hydrolase and cyclooxygenase-2 (COX-2) activities by the EtOAc fraction of B. monnieri, suggesting a plausible mechanism of action for the management of asthma. Intragastric administration of the B. monnieri extract led to a reduction of OVA-induced lung inflammation as determined by 2-D in vivo imaging using a Xenogen IVIS imaging system. Two compounds were isolated from the active fraction, namely quercetin and isochlorogenic acid A.
Conclusions: Extracts of B. monnieri exhibited significant anti-inflammatory effects both in vitro and in vivo, which supported its traditional use for the treatment of inflammatory lung disease and asthma.
Materials and Methods: Bacopa monnieri (Brahmi) leaves and stems were collected in Vidisha (M.P.), India, identified and air-dried. The dried plant materials were pulverized to a powder, extracted in methanol to exhaustion, dried and fractionated. The extracts and fractions were tested for their effects on leukotriene C4 synthase, leukotriene A4hydrolase and cyclooxygenase-2 in HL-60 cells. The active dried methanol extract of B. monnieri was then tested in vivo in an OVAinduced asthma mouse model and inflammation was assessed using 2-D imaging.
Results: Bacopa monnieri extracts and partitions inhibited leukotriene-C4-synthase, leukotriene-A4-hydrolase and/or cyclooxygenase- 2 (COX-2) activities in cultured HL-60 cells. The EtOAc partition of the extracts inhibited the activity of leukotriene-C4-synthase by 69%, and down-regulated the expression of the mRNA of this enzyme in HL-60 cells. The results demonstrated significant inhibition of leukotriene-C4-synthase, leukotriene-A4-hydrolase and cyclooxygenase-2 (COX-2) activities by the EtOAc fraction of B. monnieri, suggesting a plausible mechanism of action for the management of asthma. Intragastric administration of the B. monnieri extract led to a reduction of OVA-induced lung inflammation as determined by 2-D in vivo imaging using a Xenogen IVIS imaging system. Two compounds were isolated from the active fraction, namely quercetin and isochlorogenic acid A.
Conclusions: Extracts of B. monnieri exhibited significant anti-inflammatory effects both in vitro and in vivo, which supported its traditional use for the treatment of inflammatory lung disease and asthma.
Keywords: 2-D imaging; Asthma; Ayurveda; Brahmi; cathepsins; cyclooxygenase-2; inflammation; leukotriene-A4- hydrolase; leukotriene-C4-synthase
Document Type: Research Article
Publication date: March 1, 2014
- The journal aims to provide updates to researchers about new bioactive compounds with proven activities in various biological screenings and pharmacological models. The journal will contain information about the structures, biological activities and sources of chemical entities discovered or designed by researchers and published in leading journals. The aim is to provide a valuable information source of bioactive compounds synthesized or isolated, which can be used for further development of pharmaceuticals by industry and academia.
The journal should prove to be essential reading for pharmacologists, pharmaceutical chemists and medicinal chemists who wish to be kept informed and up-to-date with the latest and most important developments about new bioactive compounds of natural or synthetic origin, including recent patents. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Call for Papers
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content